|
|
|
|
|
| 6/17/13 | Johnson & Johnson |
Aragon Pharmaceuticals, Inc
| $650 Mln | N/A | 3Q 13 |
Johnson & Johnson ( JNJ) announced today a definitive agreement to acquire Aragon Pharmaceuticals, Inc.,
a privately-held, pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers.
Under the terms of the agreement, Johnson & Johnson will make an upfront cash payment of $650 million,
plus additional contingent payments of up to $350 million based on reaching predetermined milestones.
The transaction is expected to close in the third quarter |
| 6/17/13 | Earthlink Inc. |
CenterBeam, Inc
| $22 Mln | N/A | 3Q 13 | EarthLink, Inc. (ELNK), a leading IT services and communications provider, today announced an
agreement to acquire CenterBeam, Inc., a privately held information technology managed service
provider with a 13-year track record of delivering cloud computing and hosted IT services, for
a total consideration of $22 million. The transaction is structured as an asset purchase and is
expected to close early in the third quarter of 2013, subject to customary closing conditions.
With this acqu |
| 6/17/13 | Johnson & Johnson |
Aragon Pharmaceuticals Inc.
| Upfront $650 Mln | N/A | 3Q13 | Johnson & Johnson (JNJ) announced a definitive agreement to acquire Aragon Pharmaceuticals, Inc., a privately-held, pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers.
Under the terms of the agreement, Johnson & Johnson will make an upfront cash payment of $650 million, plus additional contingent payments of up to $350 million based on reaching predetermined milestones. The transaction is expected to close in the third quarter of 2013.
|
| 6/17/13 | Teva Pharmaceutical Industries Limited |
MicroDose Therapeutx
| $40 Mln | N/A | N/A | Teva Pharmaceutical Industries Ltd. (TEVA) today announced that it has entered into a definitive agreement
to acquire MicroDose Therapeutx, a privately-held pharmaceutical and drug delivery company
focused on inhalation technologies and products for lung diseases and infections with the
potential to dramatically improve efficacy and patient compliance.
Under the terms of the deal, Teva will acquire all of MicroDose’s outstanding shares for a payment at closing of $40 million,
addition |
| 6/17/13 | EMCOR Group Inc. |
RepconStrickland, Inc.
| $455 million | N/A | Early July | EMCOR Group, Inc. (EME) today announced that it has entered into a definitive agreement to acquire RepconStrickland, Inc. (“RepconStrickland”), a leading provider of recurring turnaround and specialty services to the North American refinery and petrochemical markets. EMCOR is acquiring the privately held company in an all cash transaction valued at approximately $455 million from its shareholders, including its majority shareholder, an affiliate of ArcLight Capital Partners, LLC, an energy focus |
|
|
|
|
|
|